Laboratoires Thea: Dry Eye Syndromes trials

The registry lists 14 Dry Eye Syndromes studies with Laboratoires Thea as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 1Phase 3 2Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.CompletedNCT06375499Not applicableResults posted
• Performance and Safety of T2769 in DEDCompletedNCT05965778Not applicableResults posted
• Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.CompletedNCT05931861Not applicableResults posted
• Efficacy of T2259 in DEDCompletedNCT03874429Not applicableResults posted
• Efficacy, Safety of T2769 in Dry Eye DiseaseCompletedNCT03830359Not applicableResults posted
• Efficacy and Safety of T2762 and Vismed® in Dry Eye SyndromeCompletedNCT02023268Phase 3Results posted
• Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye SyndromeCompletedNCT01568593Phase 3Results posted
• A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS StudyCompletedNCT07234318
• Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye DiseaseCompletedNCT07007702
• New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry EyeCompletedNCT06903741Not applicable
• Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily TreatmentCompletedNCT04803240
• Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye SyndromeTerminatedNCT02617095Not applicable
• Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis PatientsCompletedNCT01203540Phase 4
• Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye SyndromeCompletedNCT00357201Phase 2